Skip to content Skip to footer
Subscribe Now
Telix Pharmaceuticals
NEWS

Telix Reports First US Patient Dosing in the P-III Trial of Illuccix and Gozellix, for the Diagnosis of Prostate Cancer

Shots: The company has reported dosing of the first patient in the US  P-III (BiPASS) trial evaluating its PSMA-PET imaging agents, Illuccix and Gozellix, for use in the initial diagnosis of prostate cancer BiPASSa P-III study enrolling 250 pts in the US and Australia to support marketing authorization of 68Ga-PSMA-PET in the pre-biopsy setting Building…
January 19, 2026

Read more

NEWS

Telix to Acquire Therapeutic Assets & Biologics Platform from ImaginAb for ~$230M

Shots: Telix to acquire next-gen. therapeutic pipeline, biologics tech platform as well as research facility focused on protein engineering & discovery from ImaginAb via an asset purchase agreement to bolster its capabilities As per the terms, Telix will acquire candidates incl. DLL3 & integrin αvβ6 antagonist, plus a tech platform utilizing small engineered Ab…
January 13, 2025

Read more